XML 48 R35.htm IDEA: XBRL DOCUMENT v3.22.2
REVENUES - Disaggregation of Revenues (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Disaggregation of Revenue [Line Items]        
Total revenues $ 6,260 $ 6,217 $ 12,850 $ 12,640
U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 4,339 4,233 8,694 8,493
Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 1,076 1,192 2,277 2,528
Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 844 792 1,878 1,619
Total product sales        
Disaggregation of Revenue [Line Items]        
Total revenues 6,138 6,152 12,672 12,492
Total product sales | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 4,254 4,213 8,582 8,453
Total product sales | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 1,042 1,147 2,216 2,422
Total product sales | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 842 792 1,873 1,617
Total HIV        
Disaggregation of Revenue [Line Items]        
Total revenues 4,228 3,938 7,935 7,588
Total HIV | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 3,383 3,044 6,245 5,830
Total HIV | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 562 596 1,112 1,174
Total HIV | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 282 298 577 584
Biktarvy        
Disaggregation of Revenue [Line Items]        
Total revenues 2,556 1,994 4,707 3,818
Biktarvy | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 2,095 1,586 3,801 3,051
Biktarvy | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 268 237 529 453
Biktarvy | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 193 171 376 314
Complera/Eviplera        
Disaggregation of Revenue [Line Items]        
Total revenues 54 62 99 125
Complera/Eviplera | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 20 20 37 45
Complera/Eviplera | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 31 39 55 73
Complera/Eviplera | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 3 3 7 7
Descovy        
Disaggregation of Revenue [Line Items]        
Total revenues 460 435 834 794
Descovy | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 397 357 708 639
Descovy | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 32 44 64 86
Descovy | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 32 34 63 69
Genvoya        
Disaggregation of Revenue [Line Items]        
Total revenues 582 706 1,164 1,379
Genvoya | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 482 551 939 1,057
Genvoya | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 72 100 149 206
Genvoya | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 29 55 76 116
Odefsey        
Disaggregation of Revenue [Line Items]        
Total revenues 364 382 703 749
Odefsey | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 255 258 487 498
Odefsey | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 97 111 193 224
Odefsey | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 12 13 23 27
Stribild        
Disaggregation of Revenue [Line Items]        
Total revenues 33 51 66 97
Stribild | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 24 35 46 66
Stribild | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 8 11 16 22
Stribild | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 2 5 5 9
Truvada        
Disaggregation of Revenue [Line Items]        
Total revenues 34 108 72 243
Truvada | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 24 94 52 213
Truvada | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 5 6 9 13
Truvada | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 5 8 11 17
Revenue share - Symtuza        
Disaggregation of Revenue [Line Items]        
Total revenues 126 129 258 264
Revenue share - Symtuza | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 80 86 166 175
Revenue share - Symtuza | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 42 40 86 84
Revenue share - Symtuza | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 4 3 6 5
Other HIV        
Disaggregation of Revenue [Line Items]        
Total revenues 18 71 33 119
Other HIV | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 5 57 10 86
Other HIV | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 9 8 13 13
Other HIV | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 4 6 9 20
Veklury        
Disaggregation of Revenue [Line Items]        
Total revenues 445 829 1,980 2,285
Veklury | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 41 416 843 1,236
Veklury | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 126 264 430 652
Veklury | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 278 149 708 397
Total HCV        
Disaggregation of Revenue [Line Items]        
Total revenues 448 549 847 1,059
Total HCV | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 263 327 462 585
Total HCV | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 94 93 189 228
Total HCV | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 91 129 196 246
Ledipasvir/Sofosbuvir        
Disaggregation of Revenue [Line Items]        
Total revenues 23 62 58 118
Ledipasvir/Sofosbuvir | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 6 30 19 49
Ledipasvir/Sofosbuvir | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 4 3 8 19
Ledipasvir/Sofosbuvir | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 13 29 31 50
Sofosbuvir/Velpatasvir        
Disaggregation of Revenue [Line Items]        
Total revenues 376 442 706 823
Sofosbuvir/Velpatasvir | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 227 262 389 476
Sofosbuvir/Velpatasvir | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 75 82 157 157
Sofosbuvir/Velpatasvir | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 74 98 159 190
Other HCV        
Disaggregation of Revenue [Line Items]        
Total revenues 49 45 83 118
Other HCV | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 30 35 54 60
Other HCV | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 16 8 24 52
Other HCV | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 3 2 5 6
Total HBV/HDV        
Disaggregation of Revenue [Line Items]        
Total revenues 234 237 470 457
Total HBV/HDV | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 100 90 180 171
Total HBV/HDV | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 30 24 57 47
Total HBV/HDV | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 104 123 232 239
Vemlidy        
Disaggregation of Revenue [Line Items]        
Total revenues 195 200 394 381
Vemlidy | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 97 86 177 163
Vemlidy | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 9 8 18 16
Vemlidy | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 89 106 199 202
Viread        
Disaggregation of Revenue [Line Items]        
Total revenues 24 28 47 59
Viread | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 3 3 3 7
Viread | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 6 8 12 15
Viread | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 15 17 32 37
Other HBV/HBD        
Disaggregation of Revenue [Line Items]        
Total revenues 16 9 28 17
Other HBV/HBD | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 0 1 0 1
Other HBV/HBD | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 15 8 28 16
Other HBV/HBD | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 0 0 0 0
Total cell therapy        
Disaggregation of Revenue [Line Items]        
Total revenues 368 219 642 410
Total cell therapy | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 246 140 418 259
Total cell therapy | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 105 70 197 135
Total cell therapy | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 17 9 27 16
Tecartus        
Disaggregation of Revenue [Line Items]        
Total revenues 73 41 136 72
Tecartus | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 53 32 100 59
Tecartus | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 20 9 35 13
Tecartus | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 0 0 1 0
Yescarta        
Disaggregation of Revenue [Line Items]        
Total revenues 295 178 506 338
Yescarta | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 193 108 318 200
Yescarta | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 85 61 162 122
Yescarta | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 17 9 26 16
Trodelvy        
Disaggregation of Revenue [Line Items]        
Total revenues 159 89 305 161
Trodelvy | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 120 89 240 161
Trodelvy | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 35 0 61 0
Trodelvy | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 3 0 5 0
Total other        
Disaggregation of Revenue [Line Items]        
Total revenues 256 291 493 532
Total other | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 101 107 195 211
Total other | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 88 100 169 186
Total other | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 67 84 129 135
AmBisome        
Disaggregation of Revenue [Line Items]        
Total revenues 132 156 275 277
AmBisome | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 15 13 40 25
AmBisome | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 63 69 129 135
AmBisome | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 54 74 107 117
Letairis        
Disaggregation of Revenue [Line Items]        
Total revenues 49 57 92 111
Letairis | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 49 57 92 111
Letairis | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 0 0 0 0
Letairis | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 0 0 0 0
Other        
Disaggregation of Revenue [Line Items]        
Total revenues 76 78 125 144
Other | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 37 37 63 75
Other | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 26 31 41 51
Other | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues 13 10 22 18
Royalty, contract and other revenues        
Disaggregation of Revenue [Line Items]        
Total revenues 122 65 178 148
Royalty, contract and other revenues | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 85 20 112 40
Royalty, contract and other revenues | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 34 45 61 106
Royalty, contract and other revenues | Other International        
Disaggregation of Revenue [Line Items]        
Total revenues $ 2 $ 0 $ 5 $ 2